Baird analyst Joel Beatty raised the firm’s price target on Amylyx (AMLX) to $19 from $10 and keeps an Outperform rating on the shares. The firm updated its model given increased confidence in Avextide’s penetration rate in PBH.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Amylyx price target raised to $16 from $14 at BofA
- Strategic Growth and Financial Flexibility Position Amylyx Pharmaceuticals for Success: Buy Rating with $16 Price Target
- Amylyx price target raised to $25 from $17 at Guggenheim
- Amylyx Pharmaceuticals Announces $164 Million Stock Offering
- Amylyx 17.5M share Spot Secondary priced at $10.00